

CITATION REPORT

List of articles citing

A Pooled Analysis of Clinical Pharmacology Trials Investigating the Pharmacokinetic and Pharmacodynamic Characteristics of Fast-Acting Insulin Aspart in Adults with Type 1 Diabetes

DOI: 10.1007/s40262-017-0514-8

Clinical Pharmacokinetics, 2017, 56, 551-559.

Source: <https://exaly.com/paper-pdf/66042453/citation-report.pdf>

Version: 2024-04-28

This report has been generated based on the citations recorded by exaly.com for the above article. For the latest version of this publication list, visit the link given above.

The third column is the impact factor (IF) of the journal, and the fourth column is the number of citations of the article.

#	Paper	IF	Citations
124	Pharmacokinetic Properties of Fast-Acting Insulin Aspart Administered in Different Subcutaneous Injection Regions. 2017 , 37, 503-509		21
123	Faster Aspart Versus Insulin Aspart as Part of a Basal-Bolus Regimen in Inadequately Controlled Type 2 Diabetes: The onset 2 Trial. 2017 , 40, 951-957		75
122	Pharmacotherapy options for pediatric diabetes. 2017 , 29, 481-487		1
121	Development of glucose-responsive 'smart' insulin systems. 2017 , 24, 267-278		36
120	Pharmacokinetic Properties of Fast-acting Insulin Aspart Administered in Different Subcutaneous Injection Regions: Response to the commentary by Nuggehally R. Srinivas. 2017 , 37, 885-887		
119	Adding fast-acting insulin aspart to basal insulin significantly improved glycaemic control in patients with type 2 diabetes: A randomized, 18-week, open-label, phase 3 trial (onset 3). <i>Diabetes, Obesity and Metabolism</i> , 2017 , 19, 1389-1396	6.7	31
118	Fast-Acting Insulin Aspart Improves Glycemic Control in Basal-Bolus Treatment for Type 1 Diabetes: Results of a 26-Week Multicenter, Active-Controlled, Treat-to-Target, Randomized, Parallel-Group Trial (onset 1). 2017 , 40, 943-950		115
117	Impact of improving postprandial glycemic control with intensifying insulin therapy in type 2 diabetes. 2017 , 129, 791-800		4
116	Pharmacological management of type 2 diabetes: what's new in 2017?. 2017 , 10, 1383-1394		16
115	Pharmacological Properties of Faster-Acting Insulin Aspart. 2017 , 17, 101		17
114	POSTPRANDIAL DOSING OF BOLUS INSULIN IN PATIENTS WITH TYPE 1 DIABETES: A CROSS-SECTIONAL STUDY USING DATA FROM THE T1D EXCHANGE REGISTRY. 2017 , 23, 1201-1209		16
113	Fiasp: a new faster-acting insulin aspart formulation for diabetes. 2017 , 28, 37-38		3
112	Beyond oral antidiabetics: Insulin therapy options and combinations. 2017 , 23, 53-65		
111	Greater early postprandial suppression of endogenous glucose production and higher initial glucose disappearance is achieved with fast-acting insulin aspart compared with insulin aspart. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1615-1622	6.7	22
110	Efficacy and Safety of Rapid-Acting Insulin Analogs in Special Populations with Type 1 Diabetes or Gestational Diabetes: Systematic Review and Meta-Analysis. 2018 , 9, 891-917		15
109	Efficacy and safety of fast-acting insulin aspart in comparison with insulin aspart in type 1 diabetes (onset 1): A 52-week, randomized, treat-to-target, phase III trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 1148-1155	6.7	50
108	Response to Comment on Russell-Jones et al. <i>Diabetes Care</i> 2017;40:943-950. Comment on Bowering et al. <i>Diabetes Care</i> 2017;40:951-957. 2018 , 41, e29-e30		1

107	Fast-acting insulin aspart in Japanese patients with type 1 diabetes: Faster onset, higher early exposure and greater early glucose-lowering effect relative to insulin aspart. 2018 , 9, 303-310		13
106	S3-Leitlinie Therapie des Typ-1-Diabetes. <i>Diabetologie Und Stoffwechsel</i> , 2018 , 13, 1-58	0.7	11
105	Therapie des Typ-1-Diabetes. <i>Diabetologie Und Stoffwechsel</i> , 2018 , 13, S120-S130	0.7	3
104	Postprandial hyperglycemia: a new frontier in diabetes management?. 2018 , 12, 108		5
103	Fast-acting insulin aspart versus insulin aspart in the setting of insulin degludec-treated type 1 diabetes: Efficacy and safety from a randomized double-blind trial. <i>Diabetes, Obesity and Metabolism</i> , 2018 , 20, 2885-2893	6.7	31
102	11th Annual Symposium on Self-Monitoring of Blood Glucose: April 12-14, 2018, Oslo, Norway. 2018 , 20, 857-880		
101	Recent Updates on Type 1 Diabetes Mellitus Management for Clinicians. <i>Diabetes and Metabolism Journal</i> , 2018 , 42, 3-18	5	19
100	The effect of basal-bolus therapy varies with baseline 1,5-anhydroglucitol level in people with Type 2 diabetes: a post hoc analysis. 2018 , 35, 1273		1
99	Pharmacotherapy of type1 diabetes in children and adolescents: more than insulin?. 2018 , 9, 157-166		4
98	Emerging Technologies for Diabetes Care. 2018 , 20, S278-S284		21
97	ISPAD Clinical Practice Consensus Guidelines 2018: Insulin treatment in children and adolescents with diabetes. 2018 , 19 Suppl 27, 115-135		94
96	Possible Ways to Improve Postprandial Glucose Control in Type 1 Diabetes. 2018 , 20, S224-S232		18
95	Faster Insulin Aspart: A New Bolus Option for Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 421-430	4.30	11
94	[Insulin therapy-new insulin analogues]. 2019 , 60, 887-894		1
93	Glycaemic variability: The under-recognized therapeutic target in type 1 diabetes care. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2599-2608	6.7	21
92	Postprandial Glucose Control in Type 1 Diabetes: Importance of the Gastric Emptying Rate. 2019 , 11,		6
91	Pharmacotherapy of Children and Adolescents with Type 1 Diabetes Mellitus. 2020 , 261, 105-118		2
90	Use of Insulin in Outpatient Diabetes Management. 2019 , 541-554		

89	Timing of Insulin with Meals in the Hospital: a Systems Improvement Approach. 2019 , 19, 110		1
88	Short-term fully closed-loop insulin delivery using faster insulin aspart compared with standard insulin aspart in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2718-2722	6.7	8
87	Fast-Acting Insulin Aspart: The Rationale for a New Mealtime Insulin. 2019 , 10, 1793-1800		6
86	Il trattamento del diabete di tipo 1: dalle nuove insuline ai farmaci orali. 2019 , 20, 21-26		
85	Use of fast-acting insulin aspart in insulin pump therapy in clinical practice. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2039-2047	6.7	25
84	Artificial Pancreas: Current Progress and Future Outlook in the Treatment of Type 1 Diabetes. 2019 , 79, 1089-1101		17
83	Fast-acting insulin aspart in people with type 2 diabetes: Earlier onset and greater initial exposure and glucose-lowering effect compared with insulin aspart. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 2068-2075	6.7	15
82	Efficacy and Safety of Fast-Acting Insulin Aspart Compared With Insulin Aspart, Both in Combination With Insulin Degludec, in Children and Adolescents With Type 1 Diabetes: The onset 7 Trial. 2019 , 42, 1255-1262		20
81	Pharmacologic treatment options for type 1 diabetes: what's new?. 2019 , 12, 471-479		6
80	Therapie des Typ-1-Diabetes. 2019 , 15, 135-145		5
79	Fast-Acting Insulin Aspart and the Need for New Mealtime Insulin Analogues in Adults With Type 1 and Type 2 Diabetes: A Canadian Perspective. 2019 , 43, 515-523		21
78	Improving pregnancy outcomes in women with diabetes mellitus: modern management. 2019 , 15, 406-416		35
77	Efficacy and Safety of Fast-Acting Insulin Aspart in People with Type 1 Diabetes Using Carbohydrate Counting: A Post Hoc Analysis of Two Randomised Controlled Trials. 2019 , 10, 1029-1041		2
76	Elucidating the Mechanism of Absorption of Fast-Acting Insulin Aspart: The Role of Niacinamide. 2019 , 36, 49		39
75	Therapy of Type 1 Diabetes. 2019 , 127, S27-S38		7
74	Role of ultrafast-acting insulin analogues in the management of diabetes. 2019 , 31, 537-548		4
73	Are newer insulins always the better option?. 2019 , 26, 77-83		1
72	Investigating the Association Between Baseline Characteristics (HbA1c and Body Mass Index) and Clinical Outcomes of Fast-Acting Insulin Aspart in People with Diabetes: A Post Hoc Analysis. 2019 , 10, 177-188		2

71	BioChaperone Lispro versus faster aspart and insulin aspart in patients with type 1 diabetes using continuous subcutaneous insulin infusion: A randomized euglycemic clamp study. <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 1066-1070	6.7	22
70	Clinical Pharmacology of Fast-Acting Insulin Aspart Versus Insulin Aspart Measured as Free or Total Insulin Aspart and the Relation to Anti-Insulin Aspart Antibody Levels in Subjects with Type 1 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2019 , 58, 639-649	6.2	8
69	Freestyle Libre trend arrows for the management of adults with insulin-treated diabetes: A practical approach. 2019 , 33, 6-12		13
68	A randomized, multicentre trial evaluating the efficacy and safety of fast-acting insulin aspart in continuous subcutaneous insulin infusion in adults with type 1 diabetes (onset 5). <i>Diabetes, Obesity and Metabolism</i> , 2019 , 21, 961-967	6.7	34
67	Pattern Recognition Reveals Characteristic Postprandial Glucose Changes: Non-Individualized Meal Detection in Diabetes Mellitus Type 1. 2020 , 24, 594-602		7
66	Fast-Acting Insulin Aspart: A Review of its Pharmacokinetic and Pharmacodynamic Properties and the Clinical Consequences. <i>Clinical Pharmacokinetics</i> , 2020 , 59, 155-172	6.2	17
65	New Insulin to Treat Pregestational Diabetes in Pregnancy. 2020 , 76-87		
64	Biosimilars and Novel Insulins. 2020 , 27, e52-e61		3
63	Comparison of weight-based insulin titration (WIT) and glucose-based insulin titration using basal-bolus algorithm in hospitalized patients with type 2 diabetes: a multicenter, randomized, clinical study. 2020 , 8,		0
62	Aktuelle Therapien und Technologien in der Kinderdiabetologie. 2020 , 20, 12-22		
61	Use of a do-it-yourself artificial pancreas system is associated with better glucose management and higher quality of life among adults with type 1 diabetes. 2020 , 11, 2042018820950146		14
60	Therapie des Typ-1-Diabetes. 2020 , 16, 254-265		
59	New and Emerging Technologies in Type 1 Diabetes. 2020 , 49, 667-678		9
58	The association between anti-insulin aspart antibodies and the pharmacokinetic and pharmacodynamic characteristics of fast-acting insulin aspart in children and adolescents with type 1 diabetes. 2020 , 21, 781-790		1
57	Recent Advances in Insulin Therapy. 2020 , 22, 929-936		9
56	The Evolution of Insulin and How it Informs Therapy and Treatment Choices. 2020 , 41,		48
55	Pharmacokinetics of Faster and Standard Insulin Aspart During Fully Closed-Loop Insulin Delivery in Type 2 Diabetes. 2020 , 22, 691-696		3
54	The continuing quest for better subcutaneously administered prandial insulins: a review of recent developments and potential clinical implications. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 743-754	6.7	28

53	Case Report: Efficient Avoidance of Hospitalization for Diabetic Ketosis Utilizing Technosphere Inhaled Insulin. 2020 , 11, 1175-1177		
52	A survey of physician experience and treatment satisfaction using fast-acting insulin aspart in people with type 1 or type 2 diabetes. 2020 , 132, 320-327		4
51	Effect of fully automated closed-loop insulin delivery using faster aspart versus standard aspart on gluco-regulatory hormones in type 2 diabetes. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 228-233	6.7	
50	Pharmacokinetics and Pharmacodynamics of Three Different Formulations of Insulin Aspart: A Randomized, Double-Blind, Crossover Study in Men With Type 1 Diabetes. 2021 , 44, 448-455		4
49	Fast Acting Insulin Aspart Compared with Insulin Aspart in the Medtronic 670G Hybrid Closed Loop System in Type 1 Diabetes: An Open Label Crossover Study. 2021 , 23, 286-292		7
48	Impact of Fast-Acting Insulin Aspart on Glycemic Control in Patients with Type 1 Diabetes Using Intermittent-Scanning Continuous Glucose Monitoring Within a Real-World Setting: The GoBolus Study. 2021 , 23, 203-212		9
47	Glycaemic efficacy and safety of mealtime faster-acting insulin aspart administered by injection as compared to insulin aspart in people with diabetes mellitus: A meta-analysis of randomized controlled trials. 2021 , 38, e14515		7
46	Efficacy and safety of fast-acting insulin aspart versus insulin aspart in children and adolescents with type 1 diabetes from Japan. 2021 , 68, 409-420		0
45	Hybrid closed-loop glucose control with faster insulin aspart compared with standard insulin aspart in adults with type 1 diabetes: A double-blind, multicentre, multinational, randomized, crossover study. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 1389-1396	6.7	25
44	Ultra-fast insulin-pramlintide co-formulation for improved glucose management in diabetic rats.		
43	Therapie des Typ-1-Diabetes. 2021 , 17, 411-421		
42	Fast-acting insulin aspart - from insulin portraits to patient portraits. 2021 , 8-16		
41	Expert Group Recommendations on the Effective Use of Bolus Insulin in the Management of Type 2 Diabetes Mellitus. 2021 , 9,		
40	Diabetes Technology and Therapy in the Pediatric Age Group. 2021 , 23, S113-S130		
39	Improvements in Glycemic Control Achieved by Altering the t Setting in the iLet Bionic Pancreas When Using Fast-Acting Insulin Aspart: A Randomized Trial. 2021 , 12, 2019-2033		3
38	Diabetes Technology Meeting 2020. 2021 , 15, 916-960		1
37	Exploring the Burden of Mealtime Insulin Dosing in Adults and Children With Type 1 Diabetes. <i>Clinical Diabetes</i> , 2021 , 39, 347-357	2.9	0
36	Glucose control using fast-acting insulin aspart in a real-world setting: A 1-year, two-centre study in people with type 1 diabetes using continuous glucose monitoring. <i>Diabetes, Obesity and Metabolism</i> , 2021 , 23, 2716-2727	6.7	4

35	One hundred years of insulin therapy. 2021 , 17, 715-725		5
34	Fast-Acting Insulin Aspart Versus Insulin Aspart Using a Second-Generation Hybrid Closed-Loop System in Adults With Type 1 Diabetes: A Randomized, Open-Label, Crossover Trial. 2021 ,		3
33	CGM sensor glucose levels and insulin pump infusion set wear-time during treatment with fast-acting insulin aspart: a post hoc analysis of onset 5. 2021 ,		1
32	Ultra-Fast Insulin-Pramlintide Co-Formulation for Improved Glucose Management in Diabetic Rats. 2021 , 8, e2101575		2
31	Efficacy and safety of fast-acting insulin aspart compared with insulin aspart in combination with insulin degludec in Japanese adults with type 1 diabetes: a subgroup analysis of the randomized onset 8 trial. 2021 , 68, 429-440		
30	Advances in newer basal and bolus insulins: impact on type 1 diabetes. 2021 , 28, 1-7		3
29	Ultra rapid lispro lowers postprandial glucose and more closely matches normal physiological glucose response compared to other rapid insulin analogues: A phase 1 randomized, crossover study. <i>Diabetes, Obesity and Metabolism</i> , 2020 , 22, 1789-1798	6.7	29
28	Overbasalization: Addressing Hesitancy in Treatment Intensification Beyond Basal Insulin. <i>Clinical Diabetes</i> , 2020 , 38, 304-310	2.9	8
27	Glycaemic Control in People with Diabetes Starting Treatment with Fast-Acting Insulin Aspart: a US Database Study. 2021 , 12, 3067-3077		0
26	The impact of "faster aspart" on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump. 2021 , 95, 321-329		
25	Faster Insulin Aspart - a new prandial insulin analogue. 2017 , 63, 697-702		
24	Fast-acting insulin aspart: a review of its pharmacokinetic and pharmacodynamic properties and the clinical consequences. <i>Diabetes Mellitus</i> , 2020 , 23, 140-160	1.6	
23	Contrôle de la glycémie post-prandiale : apport des nouvelles formulations d'insuline ultra-rapides. <i>Medecine Des Maladies Metaboliques</i> , 2020 , 14, 718-726	0.1	
22	Indian reality of managing type 2 diabetes: an expert review of global and national guidelines for optimum insulin use. <i>Journal of Diabetology</i> , 2020 , 11, 148	0.8	1
21	[The impact of «faster aspart» on blood glucose control in children and adolescents with type 1 diabetes treated using a sensor-augmented insulin pump]. <i>Anales De Pediatrie</i> , 2020 , 95, 321-321	0.2	
20	Therapie des Typ-1-Diabetes [Kurzfassung der S3-Leitlinie (AWMF-Registernummer: 057-013; 2. Auflage). <i>Diabetologie Und Stoffwechsel</i> , 2020 , 15, S40-S50	0.7	2
19	Comparison of Pharmacokinetics and Pharmacodynamics of Inhaled Technosphere Insulin and Subcutaneous Insulin Lispro in the Treatment of Type 1 Diabetes Mellitus. <i>Clinical Pharmacokinetics</i> , 2021 , 1	6.2	0
18	Glycemic control after switching to faster aspart in adults with type 1 diabetes.. <i>Journal of Endocrinological Investigation</i> , 2022 , 1	5.2	

17 Insulin. **2022**, 263-274

16 The journey of insulin over 100 years. *Journal of Diabetology*, **2022**, 13, 8 0.8

15 Can Faster Aspart be Used to Optimize Glycemic Control With Insulin Pump Therapy? From Expectations to Lessons Learned After a Year of Use in the United States. *Clinical Diabetes*, 2.9 0

14 Rapid-Acting Insulin Analogues: Theory and Best Clinical Practice in Type 1 and Type 2 Diabetes.. *Diabetes, Obesity and Metabolism*, **2022**, 6.7 1

13 Therapie des Typ-1-Diabetes.

12 Performance of Fast-Acting Aspart Insulin as Compared to Aspart Insulin in Insulin Pump for Managing Type 1 Diabetes Mellitus: A Meta-Analysis. *Diabetes and Metabolism Journal*, 5

11 Short-acting Insulin Analogues. **2022**, 179-193

10 The Effect of Two Different Insulin Formulations on Postprandial Hyperglycemia after High and Low Glycemic-Index Meal in Type 1 Diabetes. **2022**, 14, 3316

9 The Insulin-Only Bionic Pancreas Pivotal Trial Extension Study: A Multi-Center Single-Arm Evaluation of the Insulin-Only Configuration of the Bionic Pancreas in Adults and Youth with Type 1 Diabetes. **2022**, 24, 726-736 0

8 A Multicenter Randomized Trial Evaluating Fast-Acting Insulin Aspart in the Bionic Pancreas in Adults with Type 1 Diabetes. **2022**, 24, 681-696 2

7 Livro seriado sobre Sistema de Infusão Contínua de Insulina como tecnologia educativa inovadora no diabetes. **2022**, 75, 0

6 Serial album on Continuous Insulin Infusion System as an innovative educational technology in diabetes. **2022**, 75, 0

5 Therapie des Typ-1-Diabetes. **2022**, 17, S133-S144 0

4 Efficacy and safety of ultra-rapid insulin analogues in insulin pumps in patients with Type 1 Diabetes Mellitus: A systematic review and meta-analysis. **2022**, 193, 110144 0

3 Maximizing glycemic benefits of using faster insulin formulations in type 1 diabetes: In-silico analysis under open- and closed-loop conditions. 0

2 Au-delà des insulines actuelles : des réalisations prometteuses et quelques déceptions. **2022**, 0

1 Therapie des Typ-1-Diabetes. **2023**, 21, 30-42 0